Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 987Neoplasms 796Carcinoma, Non-Small-Cell Lung 763Prostatic Neoplasms 588Colorectal Neoplasms 484Lung Neoplasms 468Neoplasm Metastasis 413Multiple Myeloma 382Leukemia, Myeloid, Acute 377Ovarian Neoplasms 316Pancreatic Neoplasms 297Melanoma 278Squamous Cell Carcinoma of Head and Neck 258Recurrence 244Carcinoma, Hepatocellular 240Brain Neoplasms 226Glioblastoma 217Triple Negative Breast Neoplasms 204Carcinoma, Renal Cell 200Head and Neck Neoplasms 198Lymphoma 193Stomach Neoplasms 190Precursor Cell Lymphoblastic Leukemia-Lymphoma 189Sarcoma 172Glioma 171Uterine Cervical Neoplasms 169Lymphoma, Non-Hodgkin 169Endometrial Neoplasms 169Lymphoma, Large B-Cell, Diffuse 166Urinary Bladder Neoplasms 160

Interventions

pembrolizumab 1enfortumab vedotin 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Muscle-invasive Bladder Cancer × 90 days × Clear all
NCT07475806 2026-05-15

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Astellas Pharma Inc

Phase 2 Recruiting
240 enrolled
Genitourinary

Muscle-invasive Bladder Cancer

NCT04660344 2026-03-27

IMvigor011

Hoffmann-La Roche

Phase 3 Active not recruiting
761 enrolled 1 FDA
Genitourinary

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡